Is there a medical correlation between mitral valve prolapse and hypermobility conditions, including Ehlers‑Danlos syndrome?

Yes, there is a well-established medical correlation between mitral valve prolapse and hypermobility conditions including Ehlers-Danlos syndrome.

Primary mitral valve prolapse (MVP) occurs with increased frequency in patients with connective tissue diseases including Ehlers-Danlos syndrome and other hypermobility conditions 1. This association is recognized in major cardiology guidelines and represents a clinically significant relationship that warrants awareness and appropriate screening.

The Evidence for This Association

Guideline Recognition

The ACC/AHA guidelines explicitly state that primary MVP occurs with increased frequency in patients with connective tissue diseases 1. The pathophysiology involves myxomatous proliferation of the mitral valve's spongiosa tissue, which shares common features with the generalized connective tissue abnormalities seen in hypermobility disorders. The guidelines note that MVP has been speculated to represent a generalized disease of connective tissue, with increased incidence in various connective tissue diseases supporting the concept of defective embryogenesis of mesenchymal cell lines 1.

Prevalence Data

The correlation is substantial but not universal:

• In adults with hypermobile Ehlers-Danlos syndrome (hEDS), MVP occurs in approximately 6.4-7.5% of patients 2, 3
• Joint hypermobility is found in 52% of patients with primary MVP 4
• Among patients with both fibromyalgia and benign joint hypermobility syndrome, MVP prevalence reaches 20%, with hypermobility increasing MVP risk approximately 9-fold 5
• The association is significantly stronger than in the general population (1-2.5% prevalence) 1

Important Clinical Nuances

The relationship is more complex than a simple one-to-one correlation:

1. Many patients with MVP have no clinically apparent connective tissue abnormality outside the heart 6. This suggests tissue-specific vulnerability rather than always representing systemic disease.

2. The severity is typically mild in hypermobility conditions. Recent studies show that while MVP is more common in hEDS/hypermobility spectrum disorders, it is rarely severe and seldom requires surgical intervention 3, 7. Over 90% of cases in females are mild, though males may have moderate-to-severe disease in up to 50% of cases 2.

3. Pediatric populations show different patterns. Recent pediatric studies found no patients with MVP among children with hEDS, suggesting the association may develop with age 8.

Clinical Implications and Screening Recommendations

Who Should Be Screened

Routine echocardiography is NOT recommended for all patients with hypermobility conditions 3. Instead, echocardiography should be performed when:

• Patients have cardiac symptoms (chest pain, palpitations, dyspnea)
• Physical examination reveals characteristic findings (midsystolic click, late systolic murmur)
• Family history of significant valvular disease
• Patients meet criteria for hEDS (where cardiac involvement is part of diagnostic criteria) 2

What to Look For

When MVP is present in hypermobility patients, assess for:

• Leaflet thickness ≥5 mm - This is the most important predictor of complications and adverse outcomes 1, 9
• Leaflet redundancy - Associated with higher risk of sudden cardiac death 10
• Degree of mitral regurgitation - Moderate to severe MR is the most frequent predictor of cardiovascular mortality 1
• Left ventricular dimensions - LVID ≥60 mm predicts need for valve replacement 1

Common Pitfalls to Avoid

1. Don't assume all hypermobility patients need echocardiograms. The yield is low in asymptomatic patients without examination findings 3, 7.

2. Don't overestimate severity based on color Doppler alone. In MVP, regurgitation may occur only in late systole, and PISA calculations can overestimate severity 11, 12.

3. Don't miss the diagnosis in patients presenting with joint complaints. Gastroenterologists and rheumatologists seeing patients with hypermobility should inquire about cardiac symptoms and consider the Beighton score for screening 13.

4. Recognize that thoracic skeletal abnormalities (straight thoracic spine, pectus excavatum) commonly associate with MVP and may be clues to the diagnosis 1.

Prognosis and Management

Most patients with MVP and hypermobility have a benign prognosis 1, 3. The natural history is heterogeneous, ranging from benign with normal life expectancy to adverse outcomes in a minority. Key management points:

• Reassurance is a major component of management for mild cases 9
• Beta-blockers are first-line for symptomatic patients with palpitations or chest pain 9
• Anticoagulation decisions follow standard MVP guidelines based on stroke risk factors 9
• Surgical intervention is rarely needed but should follow standard indications for severe MR 1

For patients with documented MVP and hypermobility, ongoing surveillance is reasonable to monitor for progressive mitral regurgitation or aortic root changes, though optimal surveillance intervals remain undefined 2.